Roche announced in August that it is buying Copenhagen-based Santaris Pharma for $250 million upfront, with another $200 million tied to undisclosed milestones. Through the move, the Basel-based pharma picks up Santaris' locked nucleic acid platform for antisense drug discovery. Roche intends to keep Santaris' Denmark operations open. The acquisition follows two Roche purchases in June: it paid $125 million upfront (another $225 million tied to potential milestones) for the sequencing company Genia Technologies and $725 million in cash plus another $1 billion in potential milestone payments for Seragon Pharmaceuticals, which is focused on oral selective estrogen receptor degraders for breast cancer.
Rights and permissions
About this article
Cite this article
Roche snaps up RNA-medicines firm Santaris. Nat Biotechnol 32, 849 (2014). https://doi.org/10.1038/nbt0914-849c
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0914-849c